跳至主要内容
临床试验/NCT06717997
NCT06717997尚未招募不适用

The Third-trimester Placental Thickness and Pregnancy Outcomes in Placenta Previa Women

Assiut University1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2025年1月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
140
试验地点
1
主要终点
number of women with placenta accreta

研究概览

简要总结

Placenta previa is the placenta overlying the cervical os. Placenta previa is about 1 in 200 pregnancies. The risk factors are the increasing rate of cesarean section and previous uterine surgery. Placenta previa is associated with many adverse complications; the most serious one is related to maternal hemorrhage. The diagnosis of placenta previa is done by trans-abdominal and trans-vaginal ultrasonography, which can document the placental edge's relationship to the internal os. Placenta accreta spectrum disorder is defined when trophoblastic invades the myometrium. The Placenta accreta spectrum can be categorized as: placenta accreta, placenta increta, and placenta percreta.

The clinical utility of placental thickness is an area of ongoing research in placenta previa. Prior studies have demonstrated an association between mid-trimester placental thickness and placenta accreta spectrum. Despite the presence of many studies in characterizing placental thickness, most studies have focused primarily on the placental accreta spectrum lacking information about other fetal and maternal complications. Symptomatic (bleeding) placenta previa is associated with increased maternal and neonatal morbidity and mortality. In addition; the mechanism that involves bleeding is unclear. It is usually related to uterine contractions, cervical effacement, and dilation leading to separation of the placenta from the underlying decidua.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
20 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •Pregnant women from 32-34 weeks.
  • •Pregnant women with singleton pregnancy.
  • •Women with placenta previa.
  • •Placenta previa with minimal vaginal bleeding or haven't any vaginal bleeding.
  • •Women without any medical disorders.
  • •Women should be living in a nearby area to make follow-up and early transportation is reasonably possible.

排除标准

  • •Women with severe bleeding necessitate immediate delivery.
  • •Women with confirmed fetal malformation.
  • •If associated with abruptio placentae.
  • •Women who will refuse to participate.

研究组 & 干预措施

Normal placental thickness women

Other

干预措施: ultrasound (Other)

High placental thickness women

Other

干预措施: ultrasound (Other)

结局指标

主要结局

number of women with placenta accreta

时间窗: 3 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mohammed Khairy Ali

Assistant Professor

Assiut University

研究点 (1)

Loading locations...

相似试验

已完成
4 期
An investigator initiated international, multicentre, stepped wedge cluster randomised study of a care bundle of physiological control strategies in acute intracerebral haemorrhage patients in comparison to usual careAcute spontaneous intracerebral haemorrhage
SLCTR/2021/003The George Institute for Global Health (Australia) Beijing Representative Office
已完成
不适用
Clinical Study Testing DNA Extracted From Tumour Tissue Biopsy Samples, Using the Therascreen® KRAS RGQ PCR KitNon-small Cell Lung Cancer
NCT05347797QIAGEN Gaithersburg, Inc495
进行中(未招募)
1 期
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of AgeCoronavirus Disease 2019
EUCTR2021-000281-15-Outside-EU/EEAModernaTX, Inc.
招募中
3 期
Evaluate the efficacy of dHACM and dHACM with PHMB in the patients with acute wounds
CTRI/2021/10/037427ifeCell International Pvt Ltd
进行中(未招募)
1 期
Afatinib (BIBW 2992) in HER2 Overexpressing Metastatic Breast Cancer Patientspatients with metastatic HER2 over-expressing breast cancerMedDRA version: 16.1 Level: PT Classification code 10057654 Term: Breast cancer female System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1 Level: PT Classification code 10065430 Term: HER-2 positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1 Level: LLT Classification code 10027475 Term: Metastatic breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2009-015476-98-GBBoehringer Ingelheim Limited745